

# MAINE STATE LEGISLATURE

The following document is provided by the  
**LAW AND LEGISLATIVE DIGITAL LIBRARY**  
at the Maine State Law and Legislative Reference Library  
<http://legislature.maine.gov/lawlib>



Reproduced from scanned originals with text recognition applied  
(searchable text may contain some errors and/or omissions)

504  
ROFS

1

L.D. 1293

2

Date: 6/8/21

(Filing No. S-220)

3

**HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES**

4

Reproduced and distributed under the direction of the Secretary of the Senate.

5

**STATE OF MAINE**

6

**SENATE**

7

**130TH LEGISLATURE**

8

**FIRST SPECIAL SESSION**

9

COMMITTEE AMENDMENT "A" to S.P. 413, L.D. 1293, "An Act To Improve Access to Certain Injectable Medications for Treatment of Mental Illness and Substance Use Disorder"

10

11

12

Amend the bill by striking out the title and substituting the following:

13

**'An Act To Improve Access to Certain Injectable Medications Approved by the Federal Food and Drug Administration'**

14

15

Amend the bill in section 2 in subsection 28 in the 11th and 12th lines (page 1, lines 26 and 27 in L.D.) by striking out the following: "to treat mental illness or substance use disorder"

16

17

18

Amend the bill in section 3 in subsection 5 in the 4th line (page 1, line 37 in L.D.) by striking out the following: "to treat mental illness or substance use disorder"

19

20

Amend the bill by inserting after section 6 the following:

21

**'Sec. 7. Appropriations and allocations.** The following appropriations and allocations are made.

22

23

**PROFESSIONAL AND FINANCIAL REGULATION, DEPARTMENT OF**

24

**Administrative Services - Professional and Financial Regulation 0094**

25

Initiative: Allocates funds for technology-related costs associated with establishing one half-time Comprehensive Health Planner I position to manage anticipated increases in applicants for certification to administer adult injections of certain drugs approved for the treatment of mental illness and substance use disorder as well as the investigation of complaints.

26

27

28

29

30

**OTHER SPECIAL REVENUE FUNDS**

**2021-22**

**2022-23**

31

All Other

\$2,729

\$3,347

32

33

**OTHER SPECIAL REVENUE FUNDS TOTAL**

\$2,729

\$3,347

34

**Licensing and Enforcement 0352**

ROFS

COMMITTEE AMENDMENT "A" to S.P. 413, L.D. 1293 (S-220)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

Initiative: Allocates funds for one half-time Comprehensive Health Planner I position and related All Other costs to manage anticipated increases in applicants for certification to administer adult injections of certain drugs approved for the treatment of mental illness and substance use disorder as well as the investigation of complaints.

<b>OTHER SPECIAL REVENUE FUNDS</b>	<b>2021-22</b>	<b>2022-23</b>
POSITIONS - LEGISLATIVE COUNT	0.500	0.500
Personal Services	\$32,875	\$45,923
All Other	\$5,712	\$2,803
<b>OTHER SPECIAL REVENUE FUNDS TOTAL</b>	<b>\$38,587</b>	<b>\$48,726</b>

**PROFESSIONAL AND FINANCIAL  
REGULATION, DEPARTMENT OF  
DEPARTMENT TOTALS**

	<b>2021-22</b>	<b>2022-23</b>
<b>OTHER SPECIAL REVENUE FUNDS</b>	<b>\$41,316</b>	<b>\$52,073</b>
<b>DEPARTMENT TOTAL - ALL FUNDS</b>	<b>\$41,316</b>	<b>\$52,073</b>

Amend the bill by relettering or renumbering any nonconsecutive Part letter or section number to read consecutively.

**SUMMARY**

This amendment changes the title and expands the scope of the bill to authorize pharmacists licensed in this State to administer to adults injections of drugs approved by the United States Food and Drug Administration upon the order of a licensed health care practitioner or as part of a collaborative practice agreement. The bill limits the administration of injectable medications to those prescribed for the treatment of mental illness and substance use disorder.

The amendment also adds an appropriations and allocations section.

**FISCAL NOTE REQUIRED**

(See attached)



# 130th MAINE LEGISLATURE

LD 1293

LR 1116(02)

## An Act To Improve Access to Certain Injectable Medications for Treatment of Mental Illness and Substance Use Disorder

Fiscal Note for Bill as Amended by Committee Amendment "A" (S-220)  
Committee: Health Coverage, Insurance and Financial Services  
Fiscal Note Required: Yes

### Fiscal Note

	FY 2021-22	FY 2022-23	Projections FY 2023-24	Projections FY 2024-25
<b>Appropriations/Allocations</b>				
Other Special Revenue Funds	\$41,316	\$52,073	\$54,828	\$57,749
<b>Transfers</b>				
Other Special Revenue Funds	\$0	\$0	\$0	\$0

#### Fiscal Detail and Notes

This bill includes Other Special Revenue Funds allocations totaling \$41,316 in fiscal year 2021-22 and \$52,073 in fiscal year 2022-23 to the Department of Professional and Financial Regulation to implement the requirements of this legislation within the Office of Professional and Occupational Licensing, Maine Board of Pharmacy.

Of this amount, allocations of \$38,587 in fiscal year 2021-22 and \$48,726 in fiscal year 2022-23 to the Licensing and Enforcement program are included to establish one half-time Comprehensive Health Planner I position and related All Other costs to manage the anticipated increase in applicants for certification to administer adult injections of certain drugs approved for the treatment of mental illness and substance use disorder, as well as the investigation of complaints. Additionally, allocations of \$2,729 in fiscal year 2021-22 and \$3,347 in fiscal year 2022-23 to the Administrative Services Division are included for technology-related costs associated with establishing the Comprehensive Health Planner I position. The Office of Professional and Occupational Licensing will transfer funds from its Licensing and Enforcement program (which includes funds for the Maine Board of Pharmacy) to the Administrative Services Division to fund the allocations.

The Maine Board of Pharmacy within the Office of Professional and Occupational Licensing has sufficient resources available to support the cost of this legislation without raising fees through the 2022-2023 biennium. However, fees may need to be increased in future biennia if the current fee structure does not generate sufficient revenue to cover the cost of this legislation.